Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.

Yang DR, Ding XF, Luo J, Shan YX, Wang R, Lin SJ, Li G, Huang CK, Zhu J, Chen Y, Lee SO, Chang C.

J Biol Chem. 2013 Jun 7;288(23):16476-83. doi: 10.1074/jbc.M112.448142. Epub 2013 Apr 22.

2.

TR4 Nuclear Receptor Alters the Prostate Cancer CD133+ Stem/Progenitor Cell Invasion via Modulating the EZH2-Related Metastasis Gene Expression.

Zhu J, Yang DR, Sun Y, Qiu X, Chang HC, Li G, Shan Y, Chang C.

Mol Cancer Ther. 2015 Jun;14(6):1445-53. doi: 10.1158/1535-7163.MCT-14-0971. Epub 2015 Apr 1.

3.

Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals.

Ding X, Yang DR, Xia L, Chen B, Yu S, Niu Y, Wang M, Li G, Chang C.

Mol Cancer. 2015 Jan 27;14:16. doi: 10.1186/s12943-014-0281-1.

4.

Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.

Tian J, Lee SO, Liang L, Luo J, Huang CK, Li L, Niu Y, Chang C.

J Biol Chem. 2012 Nov 16;287(47):39954-66. doi: 10.1074/jbc.M112.395574. Epub 2012 Sep 25.

5.

TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling.

Ding X, Yang DR, Lee SO, Chen YL, Xia L, Lin SJ, Yu S, Niu YJ, Li G, Chang C.

Int J Cancer. 2015 Feb 15;136(4):955-64. doi: 10.1002/ijc.29049. Epub 2014 Jul 14.

6.

TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals.

Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G, Yang G, Chang C.

Oncotarget. 2015 Jun 20;6(17):15397-409.

7.

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status.

Lin SJ, Lin CY, Yang DR, Izumi K, Yan E, Niu X, Chang HC, Miyamoto H, Wang N, Li G, Chang C.

Neoplasia. 2015 Apr;17(4):339-47. doi: 10.1016/j.neo.2015.02.005.

8.

The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.

Chen B, Yu S, Ding X, Jing C, Xia L, Wang M, Matro E, Rehman F, Niu Y, Li G, Chang C.

Cancer Gene Ther. 2014 Oct;21(10):411-5. doi: 10.1038/cgt.2014.41. Epub 2014 Aug 8.

PMID:
25104727
9.

Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.

Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S, Chang C.

Oncogene. 2014 May 22;33(21):2768-78. doi: 10.1038/onc.2013.233. Epub 2013 Jun 24.

PMID:
23792449
10.

miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.

Yu J, Lu Y, Cui D, Li E, Zhu Y, Zhao Y, Zhao F, Xia S.

Oncol Rep. 2014 Feb;31(2):910-8. doi: 10.3892/or.2013.2897. Epub 2013 Dec 5.

PMID:
24317363
11.

Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease.

Du L, Bergsneider M, Mirsadraei L, Young SH, Jonker JW, Downes M, Yong WH, Evans RM, Heaney AP.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):8555-60. doi: 10.1073/pnas.1306182110. Epub 2013 May 7.

12.

Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor.

Williamson SC, Hepburn AC, Wilson L, Coffey K, Ryan-Munden CA, Pal D, Leung HY, Robson CN, Heer R.

PLoS One. 2012;7(11):e48944. doi: 10.1371/journal.pone.0048944. Epub 2012 Nov 7.

13.

Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer.

Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M, Ozen M.

Prostate. 2014 Nov;74(15):1498-505. doi: 10.1002/pros.22867. Epub 2014 Aug 29.

PMID:
25175483
14.

New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.

Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, Yamashita S, Liang L, Tian J, Li L, Jiang Q, Huang CK, Niu Y, Yeh S, Chang C.

J Mol Cell Biol. 2013 Feb;5(1):14-26. doi: 10.1093/jmcb/mjs042. Epub 2012 Jul 24.

15.

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH.

PLoS One. 2008 Jul 9;3(7):e2637. doi: 10.1371/journal.pone.0002637.

16.

Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer.

Yu S, Wang M, Ding X, Xia L, Chen B, Chen Y, Zhang Z, Niu Y, Li G, Chang C.

Prostate. 2015 Oct;75(14):1632-42. doi: 10.1002/pros.23044. Epub 2015 Jul 14.

PMID:
26178291
17.

Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response.

Yan J, Tang D.

Exp Cell Res. 2014 Oct 15;328(1):132-42. doi: 10.1016/j.yexcr.2014.08.016. Epub 2014 Aug 20.

PMID:
25149681
18.

TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system.

Lin SJ, Lee SO, Lee YF, Miyamoto H, Yang DR, Li G, Chang C.

Carcinogenesis. 2014 Jun;35(6):1399-406. doi: 10.1093/carcin/bgu052. Epub 2014 Feb 28.

19.

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.

Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG.

Prostate. 2009 Nov 1;69(15):1683-93. doi: 10.1002/pros.21018.

PMID:
19644960
20.

CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).

Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.

Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.

Items per page

Supplemental Content

Write to the Help Desk